(3S,4R)-4-(4-Fluorophenyl)-3-Hydroxymethyl-1-Methylpiperidine

We are (3S,4R)-4-(4-Fluorophenyl)-3-Hydroxymethyl-1-Methylpiperidine CAS:105812-81-5 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:  (3S,4R)-4-(4-Fluorophenyl)-3-Hydroxymethyl-1-Methylpiperidine
CAS.NO:  105812-81-5
Synonyms:
(3S,4R)-4-(4-Fluorophenyl)-1-methyl-3-piperidinemethanol
(3S,4R)-4-(4′-Fluorophenyl)-3-hydroxymethyl-1-methylpiperidine
(3S,4R)-4-(4-Fluorophenyl)-3-hydroxymethyl-1-methylpiperidine

Molecular Formula: 105812-81-5
Molecular Weight:  223.28700

Physical and Chemical Properties:
Density: 1.092g / cm3
Boiling point: 300.3ºC at 760mmHg
Melting point: 97-101ºC
Flash point: 135.4ºC
Refractive index: 1.518

Specification:
Appearance:  white to light yellow crystal powder
Purity:≥98%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage: Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:
Intermediates of Paroxetine Mesylate CAS:217797-14-3
Intermediates of Paroxetine hydrochloride CAS:78246-49-8
Intermediates of Paroxetine CAS:61869-08-7

Related News: Characteristic APIs represented by cardiovascular, antiviral, antitumor and other categories are targeted at generic APIs with patent expiring original research drugs, which have high scientific and technological content and rich profits. They have developed in China in the past decade. The more active API segment has contributed to the rise of Huahai Pharmaceutical, Chuangnuo Pharmaceutical, and Jiangbei Pharmaceutical.1,2-Bis(triethoxysilyl)ethane CAS:16068-37-4 Under the terms of the agreement, ICIG will purchase substantially all of the pharmaceutical intermediates business, excluding the drug delivery technologies portion of the business.5-Fluoro-2-methyl-3-nitrobenzoic acid CAS:850462-64-5 The glucagon-only configuration may be helpful in rare conditions that often lead to chronic, low blood-sugar conditions, such as congenital hyperinsulinism (CHI).1-bromo-2-metilbutano CAS:10422-35-2 Rigosertib, Onconova’s lead candidate, is a proprietary Phase 3 small molecule.The slowdown of pesticide intermediates has dragged down the growth of industrial business. In the future, the pharmaceutical intermediate business will be the focus of the company’s development.